OLMESARTAN AMLO HCT GPPL; OLMESART AMLO HCT; OLMEKAR HCT; OLMES AMLO HCT; OLMETAN AMLO HCT (Generic Partners Pty Ltd)
Product name
OLMESARTAN AMLO HCT GPPL; OLMESART AMLO HCT; OLMEKAR HCT; OLMES AMLO HCT; OLMETAN AMLO HCT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
176 working days (255)
Active ingredients
Olmesartan medoxomil; Hydrochlorothiazide; amlodipine besilate
Registration type
New generic medicine
Indication
OLMESART AMLO HCT GPPL, OLMESART AMLO HCT, OLMEKAR HCT, OLMETAN AMLO HCT, OLMESARTAN AMLO HCT GPPL, OLMES AMLO HCT, OLMEKAR HCT, are indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. This fixed dose combination is not indicated for initial therapy.